Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.49 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.44 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | CD38 | P28907 | 10/20 | 0.43 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745367 | 0.77 | DYRK1A (0.46) | DYRK1ADYRK2DYRK1BCD38PDE10A | |
| SCHEMBL1872880 | 0.74 | DYRK1A (0.55) | DYRK1ADYRK2DYRK1BCD38MAPT | |
| SCHEMBL1896511 | 0.73 | DYRK1A (0.65) | DYRK1ANFATC1UHRF1MAP4K4 | |
| SCHEMBL30308690 | 0.73 | DYRK1A (0.65) | DYRK1ANFATC1UHRF1MAP4K4 | |
| SCHEMBL9289353 | 0.73 | CD38 (0.53) | DYRK1ADYRK2DYRK1BCD38 | |
| SCHEMBL12247658 | 0.73 | CYP2E1 (0.47) | DYRK1AUHRF1MAPT | |
| SCHEMBL19219067 | 0.72 | DYRK1A (0.53) | DYRK1ADYRK2DYRK1BCD38MAPT | |
| SCHEMBL26260195 | 0.72 | DYRK1A (0.49) | DYRK1ADYRK2DYRK1BCD38MAPT | |
| SCHEMBL4541085 | 0.72 | CD38 (0.49) | DYRK1ADYRK2DYRK1BCD38MAPT | |
| SCHEMBL16159308 | 0.72 | DYRK1A (0.47) | DYRK1ADYRK2DYRK1BCD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019149260-A1 | PYRIDAZINOL COMPOUND, DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | 青岛清原化合物有限公司 | 2019-08-08 | — | — | WO | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | DYRK1A 1092/4885NFATC1 4637/4885DYRK2 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.